Table 3.
Rate of change in renal function by CKD stage
| Variable | CKD Stage 1 (n=389) | CKD Stage 2 (n=627) | CKD Stage 3 (n=235) | |||
|---|---|---|---|---|---|---|
| Tolvaptan (n=227) | Placebo (n=162) | Tolvaptan (n=411) | Placebo (n=216) | Tolvaptan (n=151) | Placebo (n=84) | |
| Rate of eGFR decline (95% CI), ml/min per 1.73 m2 per yr | −2.15 (−2.56 to −1.75) | −2.55 (−3.20 to −1.90) | −2.76 (−3.07 to −2.45) | −3.90 (−4.42 to −3.37) | −3.70 (−4.04 to −3.36) | −5.36 (−6.19 to −4.53) |
| Treatment effect (95% CI), ml/min per 1.73 m2 per yr | 0.4 (−0.25 to 1.05) | 1.13 (0.61–1.66) | 1.66 (0.83–2.45) | |||
| P value | 0.23 | <0.001 | <0.001 | |||
| Relative treatment effect, % | 15.5 | 29.1 | 31.0 | |||
95% CI, 95% confidence interval.